Clinical trials: Locally Advanced Cervical Cancer
Non-HPV Locally Advanced Head and Neck Cancer
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of radiation therapy plus cisplatin in patients who have head and neck cancer that is not related to the human papillomavirus (HPV).
- Trial name
- TRYHARD (NCT01711658)
- Testing
- IMRT, Cisplatin, Lapatinib
- Where
- 16 sites in United States, Canada
- Volunteers
- 142 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell…
- Trial name
- NCT05343325
- Testing
- Tislelizumab, Low-dose radiotherapy
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Gastric Cancer, Esophageal Cancer
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
The INTEGA study assesses therapy Options for advanced or metastatic esophagogastric Adenocarcinoma in patients overexpressing human epidermal receptor type 2 (HER2 positive patients).
- Conditions
- Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric, HER2 Positive Gastric Cancer
- Trial name
- INTEGA (NCT03409848)
- Testing
- Nivolumab, Ipilimumab
- Where
- 35 sites in Germany
- Volunteers
- 97 people
- Sponsor
- AIO-Studien-gGmbH
Uterine Cervical Neoplasms
Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer
The purpose of this study is to image tumour lactate in study participants with locally advanced cervical cancer. Our hypothesis is that lactate content in cervical tumours, as measured by hyperpolarized 13C Magnetic Resonance…
- Trial name
- NCT03129776
- Testing
- Hyperpolarized 13C-Pyruvate, 18F-FDG
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Sunnybrook Health Sciences Centre
Esophageal Cancer
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous…
- Trial name
- NCT01267578
- Testing
- vaccination
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
Head and Neck Squamous Cell Carcinoma, Selenium
Sodium Selenite Supplementation in Patients With Head and Neck Cancer
The micronutrient selenium is an essential trace element in the human body. There are more than 25 proteins in the human body contain selenium, such as glutathione peroxidase and selenoprotein, which regulate the body's…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Selenium, Sodium Selenite
- Trial name
- NCT05451576
- Testing
- Zelnite®
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Esophageal Cancer
A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell…
- Trial name
- NCT00995358
- Testing
- peptide
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Carcinoma, Squamous Cell of Head and Neck
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy with intravenous administration of cetuximab and avelumab followed by avelumab maintenance therapy in patients with locally advanced…
- Trial name
- NCT02938273
- Testing
- avelumab, radiotherapy, cetuximab
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Cervical Cancer
Clinical and Pathological Characteristics as Prognostic Factors in Locally Advanced Cervical Cancer
Locally advanced cervical cáncer continues to be a public health problem in emergent economies, even though treatment is very well standardized, recurrence rate is still high, making necessary to evaluate prognostic clinical and…
- Trial name
- NCT04537273
- Testing
- Descriptive and analytical
- Volunteers
- 1,954 people
- Sponsor
- National Institute of Cancerología
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Locally Advanced Cervical Carcinoma
Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer
The goal of this clinical trial is to investigate the utility and effectiveness of a decision aid in cisplatin-intolerant patients with locally advanced cervical cancer. The main questions it aims to answer are: 1.
- Trial name
- CECIL (NCT05701735)
- Testing
- CECIL Patient Decision Aid
- Where
- 3 sites in Philippines
- Volunteers
- 45 people
- Sponsor
- University of Santo Tomas Hospital, Philippines
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Neoplasms
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial
The Primary Objective is to evaluate the progression-free survival after treatment with docetaxel plus cisplatin plus 5-Fluorouracil (5-FU) (DCF) in comparison with cisplatin plus 5-FU (CF) in patient with locally advanced…
- Trial name
- NCT00995293
- Testing
- DOCETAXEL, CISPLATIN, 5-FLUOROURACIL
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sanofi
Esophageal Cancer
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
This study is a randomized, multi-center, open-label, phase II study of a PD-1 inhibitor (INCMGA00012) versus observation as consolidation therapy after definitive concurrent chemoradiotherapy in patients with locally advanced…
- Trial name
- RHAPSODY (NCT04494009)
- Testing
- INCMGA00012
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center